Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al

Arthritis Rheumatol. 2017 Apr;69(4):863-865. doi: 10.1002/art.39981. Epub 2017 Mar 3.

Authors

Jeffrey R Curtis¹, Grace C Wright², Vibeke Strand³, Charles S Davis⁴, Elena Hitraya⁵, Eric H Sasso⁵

Affiliations

¹ University of Alabama at Birmingham.
² New York University Langone Medical Center, New York, NY.
³ Stanford University School of Medicine, Stanford, CA.
⁴ CSD Biostatistics, Inc., Oro Valley, AZ.
⁵ Crescendo Bioscience, South San Francisco, CA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Abatacept
Adalimumab
Antirheumatic Agents*
Arthritis, Rheumatoid*
Biological Products*
Biomarkers
Humans
Methotrexate

Substances

Antirheumatic Agents
Biological Products
Biomarkers
Abatacept
Adalimumab
Methotrexate